FDA official logo
GSRS logoPFDA official logo

PATRITUMAB DERUXTECAN

UNII:3XPI7EG4W8
Formula:
Preferred Substance Name:PATRITUMAB DERUXTECAN

  • 2227102-46-5
  • ANTI-HER3 ANTIBODY-DRUG CONJUGATE U3 1402
  • IMMUNOGLOBULIN G1, ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER3) (HUMAN MONOCLONAL U3-1287 .GAMMA.1-CHAIN), COMPLEX WITH HUMAN MONOCLONAL U3-1287 .KAPPA.-CHAIN, DIMER, OCTAKIS(THIOETHER) WITH N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)GLYCYLGLYCYL-L-PHENYLALANYL-N-((2-(((1S,9S)-9-ETHYL-5-FLUORO-2,3,9,10,13,15-HEXAHYDRO-9-HYDROXY-4-METHYL-10,13-DIOXO-1H,12H-BENZO(DE)PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLIN-1-YL)AMINO)-2-OXOETHOXY)METHYL)GLYCINAMIDE
  • IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB3 (RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3, HER3)), HOMO SAPIENS MONOCLONAL ANTIBODY, CONJUGATED TO DERUXTECAN, COMPRISING A LINKER AND A CAMPTOTHECIN DERIVATIVE; GAMMA1 HEAVY CHAIN HOMO SAPIENS (1-447) (VH (HOMO SAPIENS IGHV4-34*01 (99.0%) -(IGHD) - IGHJ2*01 (100%)) (8.7.11) (1-117) - HOMO SAPIENS IGHG1*03 (100%) G1M3, NG1M1 (CH1 R120 (214) (118-215), HINGE 1-15 (216-230), CH2 (231-340), CH3 E12 (356), M14 (358) (341-445), CHS (446-447)) (123-452)), (220-220')-DISULFIDE WITH KAPPA LIGHT CHAIN HOMO SAPIENS (1'-220') (V-KAPPA (HOMO SAPIENS IGKV4-1*01 (95.0%) -IGKJ1*01 (100%)) (12.3.9) (1'-113') - HOMO SAPIENS IGKC*01 (100%) KM3 A45.1 (159), V101 (197) (114'-220')); DIMER (226-226'':229-229'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELL LINE, GLYCOFORM ALFA; CONJUGATED, ON AN AVERAGE OF 8 CYSTEINYL, TO DERUXTECAN, COMPRISING A LINKER AND A CAMPTOTHECIN DERIVATIVE
  • PATRITUMAB DERUXTECAN [INN]
  • PATRITUMAB DERUXTECAN [JAN]
  • PATRITUMAB DERUXTECAN [USAN]
  • PATRITUMAB DERUXTECAN [WHO-DD]
  • U31402
  • U3-1402
  • U3-1402A




UNII - 3XPI7EG4W8 | UNII Search Service